|View printer-friendly version|
|July 19, 2005 11:33 a.m.|
|Teva Announces Record Global In-Market Copaxone® Sales of $291 Million in The Second Quarter, an Increase of 29%|
Sales in The Last 12 Months Crossed The 1 Billion Dollar Mark
Jerusalem, Israel, July 19, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached record $291 million in the second quarter of 2005, an increase of 29% over the comparable quarter of 2004.